Airbag Inflator Problems Cause Injury For Another Honda Driver

Problems with recalled Takata airbag inflators continue to occur, with a recent report suggesting that a Florida driver of a Honda Civic suffering severe injuries after an inflator exploded and sent pieces of shrapnel into his neck. 

Honda confirmed this week that the airbag explosion occurred on March 20, following an auto accident involving a 2003 Honda Civic. Neither the driver’s identity nor the extent of the injuries have been revealed.

The incident came a day after Honda announced it was recalling an additional 100,000 vehicles equipped with airbag inflators manufactured by Takata, a Japanese parts supplier. The move brings the total number of Honda vehicles linked to the airbag recall to about 5.5 million, which makes the company the hardest hit of any auto maker.

Learn More About

Takata Airbag Lawsuits

Millions of Vehicles Were Recalled in 2014 Due to Exploding Airbags That Caused Injuries and Deaths.


Over the past year, a series of airbag recalls have been issued over as a result of airbag inflator problems, where the devices overinflate and explode, sending potentially deadly shrapnel or other debris flying into the passenger’s compartment of vehicles. At least six deaths have been linked to the recalled airbag inflators, with most of the injuries and deaths have occurred in Honda vehicles.

The 2003 Honda Civic involved in the latest incident was on the list of vehicles that needed to be recalled and repaired.

According to Honda, the owner of the vehicle involved in the latest accident had been sent two notices that they should get their car repaired due to the airbag recall.

Takata Airbag Inflator Lawsuits

A growing number of product liability lawsuits over injuries or deaths caused by Takata airbag inflators are being filed nationwide, all involving similar allegations that design defects caused the airbags to overinflate and explode.

On February 5, the U.S. Judicial Panel on Multidistrict Litigation ordered all Takata airbag lawsuits filed in federal courts nationwide to be consolidated under one judge for pretrial proceedings as part of a Takata airbag MDL.

Complaints filed throughout the federal court system will be transferred to U.S. District Judge Federico Moreno in the Southern District of Florida to reduce duplicative discovery into common issues, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts.

The decision initially only affects at least five class action lawsuits filed in three different federal districts. However, more than 67 other pending actions have been identified in about 20 different districts, which will also be transferred into the Takata airbag MDL, since they raise common allegations of fact and law.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.